<DOC>
	<DOCNO>NCT02625532</DOCNO>
	<brief_summary>Exploratory , prospective , randomize , comparative , open trial control group treat assess efficacy follicular phase ovarian stimulation compare lutheal phase ovarian stimulation woman Bologna criterion poor ovarian response .</brief_summary>
	<brief_title>Early Follicular Phase v Lutheal Phase Ovarian Stimulation Bologna Criteria IVF/ICSI Cycles ( LUTEAL Trial )</brief_title>
	<detailed_description>Two arm establish , study group start ovarian stimulation luteal phase control group start ovarian stimulation follicular phase . The randomization make 2-3 day menstrual cycle , accord list random allocation treatment . After check contraindication start stimulation , patient assign treatment group . The patient control group ( follicular phase group ) start stimulation two vial 150 IU recombinant FSH + 75 IU recombinant LH ( Pergoveris® 150/75 ) . The patient study group ( luteal phase group ) perform daily urine LH test day 7th cycle start administration 150 IU recombinant FSH + 75 IU recombinant LH ( Pergoveris® 150/75 ) two vial daily 4th day LH positive test . Antagonist cetrorelix acetate ( Cetrotide® ) administration start large follicle shall equal great 14 mm . From moment control every 24-72 hour foliculometría ultrasound blood hormone analysis determination estradiol progesterone . For final oocyte maturation 2 vial daily 0.2 mg triptorelin acetate ( Decapeptyl® ) administer . Oocyte collection make transvaginal ultrasound-guided puncture accord IB protocol The dosage protocols use usual patient diagnostic poor ovarian response .</detailed_description>
	<criteria>Patient Bologna meet criterion diagnose low responder Age 41 year Regular menstrual cycle 21 35 day Indication vitro fertilization Indication start stimulation 300 IU FSH Presence ovaries Ability participate comply study protocol Having sign write consent form Presence follicles large 10 mm randomization visit Endometriosis III / IV Concomitant uterine pathology : adenomyosis , submucosal myoma , Asherman 's syndrome ... Concurrent participation another study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Controlled Ovarian stimulation</keyword>
	<keyword>Follicular phase</keyword>
	<keyword>Luteal phase</keyword>
	<keyword>Reproductive Techniques , Assisted</keyword>
</DOC>